Health Care & Life Sciences » Biotechnology | PanGen Biotech Inc.

PanGen Biotech Inc. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
504
3,457
928
18,569
17,782
Total Accounts Receivable
366
456
837
128
95
Inventories
-
-
-
1
25
Other Current Assets
24
116
4
-
4
Total Current Assets
893
4,029
1,768
18,698
17,907
Net Property, Plant & Equipment
5,795
5,411
4,919
5,328
6,900
Total Investments and Advances
109
127
201
-
-
Intangible Assets
2,626
4,155
5,809
7,828
7,364
Other Assets
-
-
-
206
205
Total Assets
11,488
16,873
15,899
37,398
35,593
ST Debt & Current Portion LT Debt
4,922
4,724
4,940
-
-
Accounts Payable
27
69
120
162
81
Income Tax Payable
23
-
-
-
-
Other Current Liabilities
644
760
899
1,026
3,214
Total Current Liabilities
5,616
5,554
5,959
1,188
3,294
Long-Term Debt
4,246
2,619
2,711
-
-
Provision for Risks & Charges
300
466
668
904
989
Deferred Taxes
2,064
3,151
3,201
5,340
3,216
Other Liabilities
11
23
-
-
-
Total Liabilities
10,174
8,661
9,339
2,092
4,283
Common Equity (Total)
1,314
8,212
6,561
35,307
31,309
Total Shareholders' Equity
1,314
8,212
6,561
35,307
31,309
Total Equity
1,314
8,212
6,561
35,307
31,309
Liabilities & Shareholders' Equity
11,488
16,873
15,899
37,398
35,593

About PanGen Biotech

View Profile
Address
4/F, YeongtongInnoplex II
Suwon GY 16675
Korea, Republic Of
Employees -
Website http://www.pangen.com
Updated 09/14/2018
PanGen Biotech, Inc. engages in the development of biopharmaceutical products. Its products include biosimilar erythropoietin, factor VIII and biosimilar G-CSF. The company was founded on January 29, 2010 and is headquartered in Suwon, South Korea.